Disclosed is a method of producing reconstructed human skin including forming a three-dimensional hydrogel scaffold matrix by gelling a matrix solution including a type I collagen solution, forming a coating layer by coating the three-dimensional hydrogel scaffold matrix with type IV collagen, and forming an epidermis by seeding epidermal keratinocytes onto the three-dimensional hydrogel scaffold matrix having the coating layer formed thereon and performing culture.

The present disclosure provides a method of producing uniformly sized organoids/multicellular spheroids using a microfluidic device having an array of microwells. The method involves several successive steps. First, a microfluidic device containing parallel rows of microwells that are connected with a supplying channel is filled with a wetting agent. The wetting agent is a liquid that is immiscible in water. For example, the wetting agent may be an organic liquid such as oil. In the next step, the agent in the supplying channel and the microwells is replaced with a suspension of cells in an aqueous solution that contains a precursor for a hydrogel. Next, the aqueous phase in the supplying channel is replaced with the agent, which leads to the formation of an array of droplets of cell suspension in the hydrogel precursor solution, which were compartmentalized in the wells. The droplets are then transformed into cell-laden hydrogels. Subsequently, the agent in the supplying channel is replaced with the cell culture medium continuously flowing through the microfluidic device and the cells within the hydrogels are transformed into multicellular spheroids.

The present invention relates to a tissue adhesion agent having improved bio-tissue adhesiveness and bonding force by utilizing an adhesion-related gene. More specifically, a cartilage tissue adhesion composition prepared from fetal cartilage tissue-derived stem cells in which VCAN, CTGF, or EXT1 is inserted and expressed in an upregulated manner was found to show a remarkably superb adhesive force, compared to that prepared from fetal cartilage tissue-derived stem cells in which none of the genes are inserted. Accordingly, the cell composition in which the expression of VCAN, CTGF, or EXT1 is upregulated can be prepared into a tissue adhesion composition having improved bio-tissue adhesiveness and bonding force and VCAN, CTGF, or EXT1 can be provided as an additive composition for a tissue adhesion agent.

Disclosed herein are novel methods for hydrolyzing eggshell membrane (ESM). In one embodiment, the method includes cultivating thermophilic bacteria in a solution containing 1-10% (wt %) ESM to decompose the ESM into the ESM hydrolysate; wherein, the thermophilic bacteria grow on the ESM as their sole source of nutrient. In another embodiment, the method includes treating ESM with a keratinase in the presence of a reducing agent at a condition sufficient to produce the ESM hydrolysate, in which the keratinase, the reducing agent, and the ESM are present in a weight ratio of 1:120:600. The thus produced ESM hydrolysate is enriched in essential amino acids, collagen, peptides and glycosaminoglycans.

An organ implant, such as a heart implant, including a support structure having a plurality of pores and defining passages configured for the growth of blood vessels; and stem cells from at least one soft tissue source of a patient deposited into the pores of the support structure is described. The implant is configured to repair a portion of an organ of the patient.

A frame for constructing nerve tract is provided, including microcatheters, a support, and a shell. The shell is configured to contain a culture medium inside. The microcatheters are configured to culture nerve cells. The multiple microcatheters are suspended and fixed into the shell by the support, the microcatheters are arranged along a direction from one end to the other end of the shell, catheter walls of the microcatheters are provided with through holes, the nerve cells in the microcatheter cannot flow out through the through holes, and the culture medium enters the microcatheter through the through holes. A method for constructing nerve tract based on the frame described is provided, including: filling the nerve cells wrapped with a collagen hydrogel stock solution into the microcatheters, and after the collagen hydrogel stock solution is completely cross-linked, placing the frame loaded with the nerve cells in a culture device for perfusion culture.

The present disclosure provides for a cell stabilizing medium which comprises gelatin. The cell stabilizing medium help maintain cell viability, e.g., after thawing of a biological material post-cryopreservation.

Provided are an anticoagulation and anticalcification biological material and a preparation method therefor. The preparation method includes the following steps: introducing, on a biological tissue, a polymerizable reactive group, and undergoing free radical copolymerization with a zwitterion. In the present disclosure, by introducing a reactive group capable of free radical polymerization to a biological tissue and undergoing free radical copolymerization with a zwitterionic monomer, collagen in the biological tissue is crosslinked at multiple sites by means of a polymer, thereby achieving sufficient crosslinking within and between collagen fibers, improving the stability of the biological tissue, and prolonging the service life of the biological tissue. Moreover, a zwitterion is introduced to the surface of the biological tissue, to improve the anticoagulation performance, promote the in-situ endothelialization of a biological valve, and prevent the calcium element deposition.

The present disclosure relates to a hydrogel fibre comprising an ionic hydrogel and a second component in a plurality of compartments, wherein the second component is selected from a second hydrogel, a hydrophilic solution, or a mixture thereof. It is also disclosed the method to obtain the aforesaid hydrogel fibres. This disclosure also relates to a composition comprising the hydrogel fibres and a suitable carrier, and an article/kit, a bundle, a mesh or a membrane comprising the hydrogel fibre. A composition comprising an ionic hydrogel and a second component for use in medicine administered in a hydrogel fibre comprising a plurality of compartments is also disclosed.

Provided is a method for treating diseases related to cardiac tissue damage or cardiac insufficiency in a subject. The method includes the step of locally applying a mesenchymal stem cell sheet such as an umbilical cord mesenchymal stem cell sheet to the heart of the subject. Also provided are related use and compositions of the mesenchymal stem cell sheet.